Abivax SA

Abivax SA is a France-based clinical-stage biotechnology company dedicated to developing innovative therapeutics that modulate the immune response in patients with chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms, particularly through enhanced expression of microRNA-124. Its lead drug candidate, obefazimod, is an oral, once-daily small molecule currently in Phase 3 clinical trials under the ABTECT program for adults with moderately to severely active ulcerative colitis, involving 1,200 patients across 36 countries. Positive top-line results from Phase 2 induction trials were announced in July 2025, with maintenance data expected in Q2 2026. Abivax is also advancing obefazimod into Phase 2a trials for Crohn’s disease, with enrollment initiated in Q3 2024 and data anticipated in 2H 2026. Headquartered in Paris with research facilities in Montpellier and a U.S. office in Waltham, Massachusetts, the company employs 69 people and focuses primarily on inflammatory bowel diseases within the healthcare sector's biotechnology industry. Founded in 2013, Abivax continues to explore additional inflammatory indications and proprietary chemical libraries for future pipeline expansion.